CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	DeepHealth, Inc.	Unregistered Securities	Total Radnet, Inc.'s Equity	Total Radnet, Inc.'s Equity Unregistered Securities	Common Stock	Common Stock DeepHealth, Inc.	Common Stock Unregistered Securities	Additional Paid-In Capital	Additional Paid-In Capital Unregistered Securities	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021						53,548,227
Beginning balance at Dec. 31, 2021	$ 346,157			$ 228,904		$ 5			$ 342,592		$ (20,421)	$ (93,272)	$ 117,253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the equity compensation plan (in shares)						683,077	965,969
Stock-based compensation expense	15,494			15,494					15,494
Sale of economic interests in majority owned subsidiary, net of taxes	4,582			4,582					4,582
Issuance of common stock for acquisitions (in shares)								2,106,292
Issuance of common stock for acquisitions			$ 56,470		$ 56,470					$ 56,470
Contributions from noncontrolling partner	10,673			0									10,673
Change in cumulative foreign currency translation adjustment	(6,030)			(6,030)							(6,030)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	1,847			1,847							1,847
Other	(2)			(2)					(2)		1	(1)
Net income (loss)	22,194			10,918								10,918	11,276
Ending balance (in shares) at Jun. 30, 2022						57,303,565
Ending balance at Jun. 30, 2022	451,385			312,183		$ 5			419,136		(24,603)	(82,355)	139,202
Beginning balance (in shares) at Mar. 31, 2022						56,197,826
Beginning balance at Mar. 31, 2022	421,450			298,847		$ 5			409,863		(20,761)	(90,260)	122,603
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the equity compensation plan (in shares)						152,889	952,850
Stock-based compensation expense	4,693			4,693					4,693
Sale of economic interests in majority owned subsidiary, net of taxes	4,582			4,582					4,582
Contributions from noncontrolling partner	10,673			0									10,673
Change in cumulative foreign currency translation adjustment	(4,766)			(4,766)							(4,766)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	924			924							924
Other	(2)			(2)					(2)
Net income (loss)	13,831			7,905								7,905	5,926
Ending balance (in shares) at Jun. 30, 2022						57,303,565
Ending balance at Jun. 30, 2022	$ 451,385			312,183		$ 5			419,136		(24,603)	(82,355)	139,202
Beginning balance (in shares) at Dec. 31, 2022	57,723,125					57,723,125
Beginning balance at Dec. 31, 2022	$ 491,452			332,995		$ 6			436,288		(20,677)	(82,622)	158,457
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)	5,000	20,085				5,000
Issuance of common stock upon exercise of options	$ 51			51					51
Issuance of common stock under the equity compensation plan (in shares)						1,065,877	20,085
Stock-based compensation expense	17,055			17,055					17,055
Issuance of common stock, net of issuance costs (in shares)						8,711,250
Issuance of common stock, net of issuance costs	246,202			246,202		$ 1			246,201
Issuance of common stock for acquisitions (in shares)						144,227
Issuance of common stock for acquisitions	4,000			4,000					4,000
Distributions paid to noncontrolling interests	(3,523)			0									(3,523)
Change in cumulative foreign currency translation adjustment	3,650			3,650							3,650
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	1,844			1,844							1,844
Other	(2)			(2)					(2)			0
Net income (loss)	$ 275			(12,636)								(12,636)	12,911
Ending balance (in shares) at Jun. 30, 2023	67,669,564					67,669,564
Ending balance at Jun. 30, 2023	$ 761,004			593,159		$ 7			703,593		(15,183)	(95,258)	167,845
Beginning balance (in shares) at Mar. 31, 2023						58,270,290
Beginning balance at Mar. 31, 2023	493,101			327,922		$ 6			448,522		(16,978)	(103,628)	165,179
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the equity compensation plan (in shares)						538,185	5,612
Stock-based compensation expense	4,870			4,870					4,870
Issuance of common stock, net of issuance costs (in shares)						8,711,250
Issuance of common stock, net of issuance costs	246,202			246,202		$ 1			246,201
Issuance of common stock for acquisitions (in shares)						144,227
Issuance of common stock for acquisitions	4,000			4,000					4,000
Distributions paid to noncontrolling interests	(3,523)			0									(3,523)
Change in cumulative foreign currency translation adjustment	873			873							873
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	922			922							922
Other	1			1					0			1
Net income (loss)	$ 14,558			8,369								8,369	6,189
Ending balance (in shares) at Jun. 30, 2023	67,669,564					67,669,564
Ending balance at Jun. 30, 2023	$ 761,004			$ 593,159		$ 7			$ 703,593		$ (15,183)	$ (95,258)	$ 167,845